An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs IW 1973 (Primary)
- Indications Cardiovascular disorders; Diabetic nephropathies
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
- 04 Dec 2017 Topline results presented in an Ironwood Pharmaceuticals media release.
- 16 Aug 2017 Status changed from recruiting to completed.
- 08 May 2017 Data from this trial are expected in the second half of 2017, according to an Ironwood Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History